Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma

(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced clear cell carcinoma (CCC). (2) Methods: We investigated 28 consecutive patients diagnosed with...

Full description

Bibliographic Details
Main Authors: Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, Makio Shozu
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
bevacizumab
chemotherapy
ovarian cancer
progression-free survival
surgery
Online Access:https://www.mdpi.com/2072-6694/13/13/3177

Internet

https://www.mdpi.com/2072-6694/13/13/3177

Similar Items